Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Comparison and analysis of the effectiveness to high dose of aspirin and ibuprofen in acute phase of Kawasaki disease

가와사끼병의 급성기 치료에서 고용량 아스피린과 고용량 이부프로펜 사용 효과 비교 분석

  • Keum, Seung-woon (Departments of Pediatrics, Wonkwang University College of Medicine) ;
  • Oh, Yeon-kyun (Departments of Pediatrics, Wonkwang University College of Medicine) ;
  • Kim, Jong-duck (Departments of Pediatrics, Wonkwang University College of Medicine) ;
  • Yu, Seung-taek (Departments of Pediatrics, Wonkwang University College of Medicine)
  • 금승운 (원광대학교 의과대학 소아과학교실) ;
  • 오연균 (원광대학교 의과대학 소아과학교실) ;
  • 김종덕 (원광대학교 의과대학 소아과학교실) ;
  • 유승택 (원광대학교 의과대학 소아과학교실)
  • Received : 2009.03.30
  • Accepted : 2009.07.23
  • Published : 2009.08.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : We evaluated the effectiveness of treatment and cardiac complications of replacing a high dose of aspirin with a high dose of ibuprofen for children in acute phase of Kawasaki disease. We also analyzed the possibility of replacing a high dose of aspirin with a high dose of ibuprofen to prevent complications such as Reye󰡑s syndrome caused by aspirin. Methods : One hundred eight children with Kawasaki disease were admitted in the pediatrics department from January 1, 2004 to December 31, 2008. Echocardiography and laboratory tests were performed during diagnosis, and the children were followed-up at 6-8 weeks after the diagnosis. We retrospectively analyzed their characteristics and clinical results. Results : The children were assigned to receive either a high dose of aspirin with intravenous immunoglobulin (IVIG) (aspirin group) or a high dose of ibuprofen with IVIG (ibuprofen group). A total of 55 and 53 children were included in the aspirin and ibuprofen groups, respectively. The mean defervescence period was 6.5${\pm}$2.1 days in the aspirin group, and $6.9{\pm}1.9$ days in the ibuprofen group (P=0.309). The number of failed treatments, during and after treatment, was 8 in the aspirin group and 10 in the ibuprofen group (P=0.547). There were 11 initial cardiac complications in the aspirin group, and 14 in the ibuprofen group, but children who showed improvement at follow-up was 7 and 13 in the aspirin and ibuprofen groups, respectively (P=0.133). Laboratory findings were also improved in both groups. Conclusion : We can be considered whether we will replace high dose of aspirin by high dose of ibuprofen in acute phase of Kawasaki disease. Therefore, we can prevent the severe complications of aspirin use, such as Reye's syndrome.

목 적 : 합병증으로 관상동맥 질환을 일으킬 수 있는 가와사끼병의 급성기 치료에 있어 정맥용 면역 글로불린과 함께 투여하는 고용량 아스피린을 고용량 이부프로펜으로 대체하여 투약시 효과와 가와사끼병의 합병증 발생 빈도를 비교 및 분석함으로서 Reye 증후군과 같은 합병증을 유발할 수 있는 아스피린을 이보다 부작용이 적은 이부프로펜과 같은 다른 비스테로이드 항염제로의 대체 가능성을 분석하였다. 방 법 : 2004년 1월 1일부터 2008년 12월 31일까지 익산 원광대학병원 소아과에 108명의 소아가 가와사끼병으로 진단받았다. 심장 초음파 검사와 혈액 검사를 진단 시점과 진단 약 6-8주 후 시행하여 비교하였다. 본 저자들은 대상 환아들의 특성과 검사소견을 기초로 후향적으로 비교분석하였다. 결 과 : 총 108명의 환아들을 정맥용 면역글로불린 투여 및 고용량 아스피린을 사용했던 군(아스피린 군)과 정맥용 면역글로불린 투여 및 고용량 이부프로펜을 사용했던 군(이부프로펜 군)으로 분류하였다. 아스피린 군은 55명이었고 이부프로펜 군은 53명이었다. 평균 해열 기간은 발열 후 아스피린 군 $6.5{\pm}2.1$일, 이부프로펜 군 $6.9{\pm}1.9$일이었다(P=0.309). 치료 중이나 후 치료실패 환아는 아스피린 군 8명, 이부프로펜 군 10명이었다(P=0.547). 재발한 환아는 아스피린 군 2명, 이부프로펜 군 1명이었다(P=0.580). 혈액 검사에서도 두 군에서 호전된 소견을 보였다. 결 론 : 본 저자들은 가와사끼병 급성기에 있어 정맥용 면역글로불린과 더불어 사용하고 있는 고용량 아스피린 투약에 있어 이부프로펜과 같은 비스테로이드 항염제를 대체하여 투약할 수 있을 것으로 생각되며 이에 Reye 증후군과 같은 아스피린의 치명적인 합병증을 예방할 수 있을 것이다.

Keywords

Acknowledgement

Supported by : Wonkwang University

References

  1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi 1967;16:178-222
  2. Burns JC, Kushner HI, Bastian JF, Shike H, Shimizu C, Matsubara T, et al. Kawasaki disease: A brief history. Pediatrics 2000;106:E27
  3. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki disease. N Engl J Med 1991;324:1633-9 https://doi.org/10.1056/NEJM199106063242305
  4. Onouchi Z, Kawasaki T. Overview of pharmacological treatment of Kawasaki disease. Drugs 1999;58:813-22 https://doi.org/10.2165/00003495-199958050-00004
  5. Ichida F, Fatica NS, Engle MA, O'Loughlin JE, Klein AA, Snyder MS, et al. Coronary artery involvement in Kawasaki syndrome in Manhattan, New York: risk factors and role of aspirin. Pediatrics 1987;80:828-35
  6. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997;131:888-93 https://doi.org/10.1016/S0022-3476(97)70038-6
  7. Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited. Pediatrics 2004;114:e689-93 https://doi.org/10.1542/peds.2004-1037
  8. Baumer JH, Love SJ, Gupta A, Haines LC, Maconochie I, Dua JS. Salicylate for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 2006;18:CD004175
  9. Mulberg AE, Verhave M. Identification and treatment of nonsteroidal anti-inflammatory drug-induced gastroduodenal injury in children. Am J Dis Child 1993;147:1280-1
  10. Matsubara T, Mason W, Kashani IA, Kligerman M, Burns JC. Gastrointestinal hemorrhage complicating aspirin therapy in acute Kawasaki disease. J Pediatr 1996;128:701-3 https://doi.org/10.1016/S0022-3476(96)80140-5
  11. Lee JH, Hung HY, Huang FY. Kawasaki disease with Reye syndrome: report of one case. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi 1992;33:67-71
  12. Yoshikawa J, Yanagihara K, Owaki T, Kato H, Takagi Y, Okumachi F, et al. Cross-sectional echocardiographic diagnosis of coronary artery aneurysms in patients with the mucocutaneous lymph node syndrome. Circulation 1979;59:133-9 https://doi.org/10.1161/01.CIR.59.1.133
  13. Research Committee on Kawasaki disease. Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease. Tokyo, Japan: Japenase Ministry of Health and Welfare, 1984
  14. Leung DY, Meissner HC, Shulman ST, Mason WH, Gerber MA, Glode MP, et al. Prevalence of superantigen-secreting bacteria in patients with Kawasaki disease. J Pediatr 2002; 140:742-6 https://doi.org/10.1067/mpd.2002.123664
  15. Brown TJ, Crawford SE, Cornwall ML, Garcia F, Shulman ST, Rowley AH. CD8 T lymphocytes and macrophages infiltrate coronary artery aneurysms in acute Kawasaki disease. J Infect Dis 2001;184:940-3 https://doi.org/10.1086/323155
  16. Rowley AH, Eckerley CA, Jack HM, Shulman ST, Baker SC. IgA plasma cells in vascular tissue of patients with Kawasaki syndrome. J Immunol 1997;159:5946-55
  17. Rowley AH, Shulman ST, Spike BT, Mask CA, Baker SC. Oligoclonal IgA response in the vascular wall in acute Kawasaki disease. J Immunol 2001;166:1334-43
  18. Rowley AH, Shulman ST, Mask CA, Finn LS, Terai M, Baker SC et al. IgA plasma cell infiltration of proximal respiratory tract, pancreas, kidney, and coronary artery in acute Kawasaki disease. J Infect Dis 2000;182:1183-91 https://doi.org/10.1086/315832
  19. Yasukawa K, Terai M, Shulman ST, Toyozaki T, Yajima S, Kohno Y et al. Systemic production of vascular endothelial growth factor and fms-like tyrosine kinase-1 receptor in acute Kawasaki disease. Circulation 2002;105:766-9 https://doi.org/10.1161/hc0602.103396
  20. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004;114:1708-33 https://doi.org/10.1542/peds.2004-2182
  21. Rowley AH, Shulman ST. Kawasaki disease. In : Kliegman RM, Jenson HB, Behrman RE, Stanton BF, editors. Nelson textbook of pediatrics. 18th ed. Philadelphia : WB Saunders Co, 2007:1036-42
  22. Burns JC, Mason WH, Glode MP, Shulman ST, Melish ME, Meissner C, et al. Clinical and epidemiologic characteristics of patients referred for evaluation of possible Kawasaki disease. United States Multicenter Kawasaki Disease Study Group. J Pediatr 1991;118:680-6 https://doi.org/10.1016/S0022-3476(05)80026-5
  23. Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy E, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986;315: 341-7 https://doi.org/10.1056/NEJM198608073150601
  24. Crystal MA, Manlhiot C, Yeung RS, Smallhorn JF, McCrindle BW. Coronary artery dilation after Kawasaki disease for children within the normal range. Int J Cardiol 2008;1-6 https://doi.org/10.1016/j.ijcard.2008.04.019
  25. de Zorzi A, Colan SD, Gauvreau K, Baker AL, Sundel RP, Newburger JW. Coronary artery dimensions may be misclassified as normal in Kawasaki disease. J Pediatr 1998; 133:254-8 https://doi.org/10.1016/S0022-3476(98)70229-X
  26. Kurotobi S, Nagai T, Kawakami N, Sano T. Coronary diameter in normal infants, children and patients with Kawasaki disease. Pediatr int 2002;44:1-4 https://doi.org/10.1046/j.1442-200X.2002.01508.x
  27. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324:1633-9 https://doi.org/10.1056/NEJM199106063242305
  28. Behan MW, Storey RF. Antiplatelet therapy in cardiovascular disease. Postgrad Med J 2004;80:155-64 https://doi.org/10.1136/pgmj.2003.007062
  29. Dajani AS, Taubert KA, Gerber MA, Shulman ST, Ferrieri P, Freed M, et al. Diagnosis and therapy of Kawasaki disease in children. Circulation 1993;87:1776-80
  30. Dajani AS, Taubert KA, Takahashi M, Bierman FZ, Freed MD, Ferrieri P, et al. Guidelines for long-term management of patients with Kawasaki disease: Report from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 1994;89:916-22
  31. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cylooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345: 1809-17 https://doi.org/10.1056/NEJMoa003199
  32. Nahata MC, Durrell DE, Powell DA, Gupta N. Pharmacokinetics of ibuprofen in febrile children. Eur J Clin Pharmacol 1991;40:427-8 https://doi.org/10.1007/BF00265858
  33. Food and Drug Administration U.S. Department of Health and Human Services. Concomitant use of ibuprofen and aspirin. J Pain Palliat Care Pharmacother 2007;21:73-4

Cited by

  1. Comparative Study between High Dose Aspirin and Ibuprofen in the Treatment of Kawasaki Disease in the Acute Stage vol.24, pp.2, 2009, https://doi.org/10.15746/sms.18.034